Sol-Gel Technologies Ltd. (SLGL) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Sol-Gel Technologies Ltd. (SLGL) Healthcare & Pipeline Overview

Sol-Gel Technologies Ltd. is an Israeli clinical-stage specialty pharmaceutical company focused on developing and commercializing topical dermatological drug products. Leveraging its proprietary microencapsulation delivery system, the company advances a pipeline including Phase III candidates Twyneo for acne and Epsolay for rosacea, alongside generic topical dermatological products.

What Is the Investment Thesis for SLGL?

Sol-Gel Technologies Ltd. presents an investment thesis centered on its advanced clinical pipeline and proprietary microencapsulation technology in the specialized dermatological market. Key value drivers include the successful completion of Phase III clinical trials for two lead candidates, Twyneo (acne vulgaris) and Epsolay (papulopustular rosacea), positioning them for potential regulatory approval and commercialization. The company's proprietary drug delivery system offers a differentiated approach in a competitive market, aiming for improved patient compliance and therapeutic outcomes. Growth catalysts are primarily tied to the anticipated regulatory approvals and subsequent market launches of Twyneo and Epsolay, which could transform the company's financial profile from a clinical-stage entity with a -5.7% profit margin to a commercial one. Further pipeline advancements, such as SGT-210 in Phase I, and expansion in generic topical dermatological products, along with its collaboration with Perrigo, offer additional growth avenues. With a market capitalization of $218M and a gross margin of 100.0%, the company demonstrates strong product-level profitability potential once commercialized, though it carries a Beta of 1.17, indicating higher market volatility.

Based on FMP financials and quantitative analysis

SLGL Key Highlights

Gross Margin of 100.0% reflects strong product-level profitability before operating expenses, indicative of a development-stage company.

• Market Capitalization stands at $218M, positioning Sol-Gel Technologies as a clinical-stage biotechnology company with significant growth potential.
• Profit Margin of -5.7% is characteristic of a company heavily investing in research and development, prior to widespread commercialization.
• Beta of 1.17 suggests that the company's stock exhibits higher volatility compared to the broader market, consistent with a clinical-stage biotech.
• Two lead product candidates, Twyneo for acne vulgaris and Epsolay for papulopustular rosacea, have successfully completed Phase III clinical trials, nearing potential commercialization.

Who Are SLGL's Competitors?

SLGL is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are SLGL's Key Strengths?

Proprietary microencapsulation delivery system offers differentiated product profiles.

• Two lead product candidates, Twyneo and Epsolay, have successfully completed Phase III clinical trials.
• Strategic collaboration with Perrigo provides potential commercialization pathways and expertise.
• Focused specialization in the topical dermatological market addresses specific patient needs.

What Are SLGL's Weaknesses?

Currently operating at a negative profit margin, typical for a clinical-stage company.

• Dependence on successful regulatory approvals and commercialization of a limited number of lead candidates.
• Relatively small employee base (34 employees) compared to larger pharmaceutical competitors.
• Limited current product portfolio, with most value tied to future pipeline success.

What Could Drive SLGL Stock Higher?

SLGL catalyst: Potential regulatory approval for Twyneo for the treatment of acne vulgaris, following its successful completion of Phase III clinical trials.

• Potential regulatory approval for Epsolay for the treatment of papulopustular rosacea, having also completed Phase III clinical trials.
• Commercial launch of Twyneo, which would mark the company's transition from a purely clinical-stage entity to a commercial one.
• Commercial launch of Epsolay, further diversifying the company's revenue streams and market presence.
• Advancement of SGT-210 through Phase I clinical trials for the treatment of palmoplantar keratoderma, indicating pipeline progression.

What Are the Key Risks for SLGL?

Negative return on equity (-3.2%) — the business is not currently generating profit on shareholder capital.

• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Failure to obtain necessary regulatory approvals for lead product candidates, Twyneo and Epsolay, which would significantly impact future revenue generation.
• Market adoption challenges for new dermatological products, even after approval, due to competition, pricing pressures, or physician/patient preferences.
• Negative profit margin, reflecting ongoing substantial research and development expenditures without significant commercial product revenue.
• Intense competition within the topical dermatology market from established pharmaceutical companies and other clinical-stage biotechs.
• Clinical trial failures or unexpected adverse events for pipeline candidates beyond Phase III, leading to delays or discontinuation of development.

What Are the Growth Opportunities for SLGL?

• Commercialization of Twyneo for Acne Vulgaris: Twyneo, having completed Phase III clinical trials, represents a significant near-term growth opportunity. The global acne treatment market is substantial, driven by a high prevalence of the condition across various age groups. Successful regulatory approval and subsequent commercial launch of Twyneo, potentially leveraging the existing collaboration with Perrigo, could unlock a new revenue stream for Sol-Gel. The product's once-daily, non-antibiotic formulation, enabled by the proprietary microencapsulation system, offers a differentiated profile that could capture a meaningful share in this competitive market, addressing patient needs for effective and well-tolerated treatments.
• Commercialization of Epsolay for Papulopustular Rosacea: Epsolay, also having completed Phase III clinical trials, targets papulopustular rosacea, another prevalent chronic inflammatory skin condition. The market for rosacea treatments is growing, with increasing awareness and diagnostic rates. Similar to Twyneo, the successful regulatory approval and commercialization of Epsolay would provide Sol-Gel with a second significant revenue-generating product. Its once-daily topical cream formulation, utilizing the company's advanced delivery technology, aims to offer superior patient experience and clinical outcomes, thereby establishing a strong market position and contributing substantially to the company's financial growth.
• Advancement and Commercialization of SGT-210 and Other Pipeline Candidates: Sol-Gel's pipeline extends beyond its lead Phase III candidates, including SGT-210 in Phase I for palmoplantar keratoderma, and other compounds like Erlotinib, Tapinarof, and roflumilast for psoriasis and related conditions. The successful progression of these earlier-stage assets through clinical development and eventual commercialization represents long-term growth potential. Each of these conditions addresses specific dermatological needs, and successful development would diversify Sol-Gel's product portfolio, reducing reliance on its lead candidates and opening up new market segments with potentially high unmet needs and significant market sizes.
• Expansion in Generic Topical Dermatological Drug Products: Beyond its proprietary pipeline, Sol-Gel Technologies is actively involved in the development of generic topical dermatological drug products. This segment offers a more predictable, albeit lower-margin, revenue stream compared to novel drug development. Expanding the portfolio of generic products allows the company to leverage its formulation expertise and manufacturing capabilities, providing a stable base of income that can support further R&D efforts. Growth in this area can be achieved through strategic product selection, efficient development, and effective market penetration, contributing to overall financial stability and growth.
• Strategic Partnerships and Licensing Opportunities: The existing collaboration with Perrigo demonstrates Sol-Gel's capability to form strategic alliances. Future growth can be significantly driven by forging new partnerships for the development, manufacturing, or commercialization of its proprietary products in various geographies or indications. Licensing agreements for its microencapsulation technology or specific drug candidates could provide upfront payments, milestone payments, and royalties, offering non-dilutive funding and expanding market reach without direct commercialization costs. These collaborations are crucial for a clinical-stage company to maximize the value of its intellectual property and accelerate market access.

What Are SLGL's Competitive Advantages?

• Proprietary microencapsulation delivery system that enhances drug stability, efficacy, and reduces side effects for topical applications.
• Advanced clinical pipeline featuring two lead product candidates, Twyneo and Epsolay, having successfully completed Phase III trials.
• Intellectual property surrounding its unique drug formulations and delivery technologies, providing a competitive barrier.
• Specialized focus and expertise in topical dermatology, allowing for targeted development and market penetration.

What Does SLGL Do?

Sol-Gel Technologies Ltd., incorporated in 1997 and headquartered in Ness Ziona, Israel, is a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of innovative topical dermatological drug products. The company's foundational strategy revolves around its proprietary microencapsulation delivery system, designed to enhance the efficacy and safety profiles of dermatological treatments. This technology allows for controlled release and targeted delivery of active pharmaceutical ingredients, aiming to improve patient outcomes and reduce potential side effects. Over its history, Sol-Gel has evolved into a key player in the topical dermatology space, focusing on unmet medical needs within this therapeutic area. Its product pipeline features several promising candidates, including Twyneo, a novel, once-daily, non-antibiotic topical cream that has successfully completed Phase III clinical trials for the treatment of acne vulgaris. Another lead candidate, Epsolay, is a once-daily topical cream that has also completed Phase III clinical trials, specifically targeting papulopustular rosacea. Beyond these advanced-stage programs, Sol-Gel is progressing SGT-210, currently in Phase I clinical trials for palmoplantar keratoderma, and exploring other compounds such as Erlotinib, Tapinarof, and roflumilast for conditions like psoriasis. In addition to its proprietary drug development, the company is actively involved in the development of generic topical dermatological drug products, diversifying its potential revenue streams. Sol-Gel Technologies Ltd. maintains a strategic collaboration with Perrigo, further strengthening its capabilities in development and potential commercialization.

What Products and Services Does SLGL Offer?

• Develops and commercializes topical dermatological drug products.
• Utilizes a proprietary microencapsulation delivery system for enhanced drug efficacy and safety.
• Advances Twyneo, a once-daily, non-antibiotic topical cream for acne vulgaris, through regulatory processes.
• Advances Epsolay, a once-daily topical cream for papulopustular rosacea, through regulatory processes.
• Conducts clinical trials for earlier-stage candidates like SGT-210 for palmoplantar keratoderma.
• Researches and develops other compounds such as Erlotinib, Tapinarof, and roflumilast for psoriasis and other conditions.
• Develops and commercializes generic topical dermatological drug products.
• Engages in strategic collaborations, including an existing partnership with Perrigo.

How Does SLGL Make Money?

• Research and development of proprietary topical dermatological drug candidates, funded by capital raises and potential partnership milestones.
• Seeking regulatory approval for novel drug products like Twyneo and Epsolay to enable commercialization.
• Commercialization and sales of approved proprietary drug products, potentially through licensing agreements or collaborations with pharmaceutical partners.
• Development, manufacturing, and sale of generic topical dermatological products to generate revenue from established markets.

What Industry Does SLGL Operate In?

Sol-Gel Technologies Ltd. operates within the highly specialized and competitive biotechnology industry, specifically focusing on the dermatological segment of the healthcare sector. The topical dermatology market is characterized by a continuous demand for innovative treatments that offer improved efficacy, reduced side effects, and enhanced patient compliance. Sol-Gel's proprietary microencapsulation delivery system positions it within a niche that seeks to address these needs by optimizing drug delivery. The competitive landscape includes both large pharmaceutical companies with established dermatology portfolios and smaller biotech firms developing novel solutions. Sol-Gel's strategy of advancing late-stage clinical candidates like Twyneo and Epsolay, alongside a pipeline of earlier-stage and generic topical products, allows it to target significant market opportunities. The industry is driven by scientific advancements, regulatory milestones, and strategic partnerships, all of which are critical for success in bringing new dermatological therapies to market.

Who Are SLGL's Key Customers?

• Dermatologists and other healthcare professionals who prescribe topical treatments.
• Patients suffering from dermatological conditions such as acne vulgaris, papulopustular rosacea, and palmoplantar keratoderma.
• Pharmaceutical distributors and pharmacies that stock and dispense dermatological medications.
• Potential pharmaceutical partners seeking to license or co-develop advanced dermatological therapies.

Company Profile

Sol-Gel Technologies Ltd. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Ness Ziona, IL. The company is led by CEO Moshe Arkin. SLGL has traded publicly since 2018.

Sol-Gel Technologies Ltd. Financial Trajectory

Sol-Gel Technologies Ltd. (SLGL) reported $591K in revenue for Q2 FY2026, reflecting 447.2% growth compared to the prior quarter. The company recorded a net loss of $3.7M, with diluted EPS of $-1.13. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, SLGL averaged $-1.41 in diluted EPS.

How Sol-Gel Technologies Ltd. Is Valued

Sol-Gel Technologies Ltd. carries a market capitalization of $218M, placing it in the micro-cap category. Analyst price targets span from $110.00 to $110.00, with a consensus of $110.00. At the current price of $66.79, that implies approximately 65% upside potential. Relative to its peer group, SLGL's quantitative score of 30/100 is below the peer average of 77/100.

Return on equity for Sol-Gel Technologies Ltd. stands at -3.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -1.8%, showing how much profit it generates from its asset base. A current ratio of 8.84 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -0.5%, the inverse of the P/E and a quick read on earnings relative to price.

Sol-Gel Technologies Ltd.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 17.61 places it in the safe zone, indicating low near-term bankruptcy risk.

Sol-Gel Technologies Ltd. has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 35.6% above estimates on average.

Over the past six months, Sol-Gel Technologies Ltd. insiders filed 19 SEC Form 4 transactions — 0 sales and 19 purchases. On net that is roughly 92K shares acquired (about $6.4M) — insiders putting money in tends to read as conviction.

SLGL Financials

SLGL Latest News

SLGL Analyst Consensus

SLGL MoonshotScore

SLGL Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources